MedTrace Logo

DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia

NCT00241488 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1362

Last updated 2008-02-07

No results posted yet for this study

Summary

This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.

Conditions

Interventions

DRUG

Rosuvastatin

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca China Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-12-31
Completion
2007-02-28

Countries

  • China
  • Hong Kong
  • Malaysia
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241488 on ClinicalTrials.gov